Chart of the Day: Merck to Spike to $115?

 | Nov 08, 2022 21:15

Drugmaker Merck's (NYSE:MRK) stock has outperformed its competitors year to date (ytd), rising 30.6%. Pfizer (NYSE:PFE), which I am bearish on, is down 16.9% so far this year. The Rahway, New Jersey-based firm's biggest sellers included melanoma-treating KEYTRUDA, the human Papillomavirus vaccine, Gardasil, and Bridion which is used to speed up the recovery from a muscle relaxant, usually at the end of a surgical procedure.

The future looks exceptionally bright for KEYTRUDA as the US Food and Drug Administration (FDA) has approved expanded indications for the drug.

At $100.07, MRK is down 1.4% since its Oct .27 all-time high (ATH) of $101.50. The stock increased 1.35% that day after the company reported earnings and revenue ahead of expectations. Moreover, the pharmaceutical multinational raised its full-year forecast. Yet, the stock pared that day's much sharper rally of 3.14% and has been ranging with a downward bias since then. What gives?

Investors don't buy a stock based on its current value, they buy it based on its future value. That is behind the old Wall Street adage, "Buy the rumor, sell the news." That is why stocks often sell off on good news because investors have already priced it in the news so they sell to lock in profits.

Now let us examine Merck's chart.